Bruker Corporation (Nasdaq: BRKR) today announced the
acquisition of Optimal Industrial Automation and Technologies, a
leader in pharma and biopharma process analytical technology (PAT),
pharma manufacturing automation and Quality Assurance (QA) software
and systems integration, based in the United Kingdom. The Optimal
biopharma tools acquisition strengthens Bruker as a key software
and solutions provider for small molecule, biologics and new drug
modalities pharma companies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220405005227/en/
The award-winning Optimal PAT knowledge
management software synTQ® can help to optimize biopharma
manufacturing processes in real-time. (Photo: Business Wire)
Financial details of the acquisition were not disclosed.
Optimal’s 2022 revenue is expected to be approximately $10 million,
and Optimal’s revenue growth rate and operating margins are
projected to be accretive to Bruker in 2023 and beyond.
The Optimal biopharma tools and automation capabilities
complement Bruker’s innovative and differentiated high-value NMR,
mass spectrometry, SPR, molecular spectroscopy and X-ray scientific
instruments, and life-science solutions for biopharma drug
discovery and development, as well as for PAT analytical and QA
solutions. Together these biopharma tools enable Bruker’s global
biopharma customers to bring efficacious and safe medicines to
market more quickly.
Optimal has a focus on the automation and optimization of batch
and continuous processes in the biopharma industry – from R&D
to manufacturing. As an integrated PAT solutions provider, Optimal
offers development, testing, deployment and support of
quality-centric pharmaceutical production systems. Optimal has more
than 30 years of experience in successfully delivering
regulatory-compliant biopharma solutions, ranging from the
development of automated control systems for process control to the
market-leading, vendor-agnostic PAT knowledge management software
synTQ®.
The synTQ PAT software can interface between multiple analytical
instruments (spectral and univariate), multi-variate analysis (MVA)
packages, manufacturing control systems and a range of adjacent
software solutions to ensure quality in real-time.
As a 2021 Pharma Innovation Award winner, synTQ is a proven
enabler of quality-by-design (QbD) via PAT. For users of synTQ,
this can significantly increase productivity and quality, while
reducing waste, time-to-manufacture and time-to-market, with proven
Optimal use cases tripling biopharma productivity.
While remaining a vendor-agnostic biopharma solutions provider,
Optimal can integrate bioanalytical technologies such as nuclear
magnetic resonance (NMR), mass spectrometry (MS) and FTIR/NIR/Raman
systems into innovative drug discovery, development, PAT and
quality control workflows. Combining next-generation,
high-performance technologies with Optimal solutions eases the
transition from development to biopharma manufacturing, while
remaining in regulatory compliance.
Dr. Falko Busse, President of the Bruker BioSpin Group,
commented: “The acquisition of Optimal is a very exciting step for
Bruker as it supports more comprehensive solutions for the
biopharmaceutical industry, now adding the capabilities to
integrate cutting-edge systems into biopharma manufacturing
processes and workflows. We welcome the Optimal team with their
strong PAT and automation expertise and, together, are eager to
support biotech and pharmaceutical companies in increasing their
manufacturing efficiency and flexibility – a global need
highlighted by the response to the pandemic crisis.”
Mr. Martin Gadsby, the CEO and Co-Founder of Optimal Industrial
Automation and Technologies, added: “We are delighted to become
part of the Bruker family. Optimal and Bruker together are a
perfect fit – we share the common ethos of innovation with
integrity, together with our industry recognition as a high-quality
solutions provider delivering tangible benefits to our customers.
The whole Optimal team is excited by this new chapter in our
history and looks forward to delivering benefits to even more
biopharma customers and ultimately to patients around the
world.”
For more information about Optimal Industrial Automation and
Optimal Industrial Technologies, please visit:
https://www.optimal-ltd.co.uk/ , https://optimal-tech.co.uk/ and
syntq.com
For more information about Bruker’s pharmaceutical applications,
please visit:
https://www.bruker.com/en/applications/pharma.html
About Optimal Industrial Technologies and Automation
A well-established system integrator with more than 30 years of
experience, at Optimal we specialize in automating a client’s
R&D or manufacturing system to ensure that their processes
remain at the highest level of efficiency. The demands being placed
on manufacturers in relation to production costs, product quality
and business sustainability are ever increasing, and our primary
aim within Optimal is to assist you in being the most competitive
supplier of your product to the highest level of quality in the
worldwide marketplace, and to ensure that you continue to maintain
your lead in the years ahead.
We have a rare and wide-ranging skill set covering a multitude
of automation technologies, manufacturing processes and industry
types, with very specific knowledge in highly regulated
environments. In addition, we manufacture the world leading PAT
Data Management software package - synTQ® and the widely used
integrated Print and Inspect system - synTI®. The combination of
our PAT implementation knowledge and synTQ® product together with
our automation experience positions us with unique skills that can
be leveraged to great advantage by our customers.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220405005227/en/
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 663-3660 x1479 E: Investor.Relations@bruker.com
Media Contact: Thorsten Thiel, Ph. D. VP of Group
Marketing Bruker BioSpin T: +49 (721) 5161–6500 E:
pr@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024